Sun, Oct 26, 2014, 4:15 AM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

ONYX Pharmaceuticals, Inc. Message Board

testaccount70 1 post  |  Last Activity: Aug 14, 2014 8:42 AM Member since: Jan 17, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Selling because of the results of FOCUS makes no sense to me because it was a poorly designed study. The trial compares two active arms in heavily pretreated patients in which Kyprolis was used at the standard dose, which no one believes is the optimal dose of the drug. The control arm was a steroid with the option of a Dr. adding cyclophosphamide if he/she wanted to (and almost all did) - Why was there not a third arm that combined steroid/cyclo + Kyprolis? The way this study was designed is the major reason for its failure, not the drug.
    EU approval will go forward with the better designed ASPIRE data set.

    Sentiment: Buy

124.700.00(0.00%)Sep 30 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
NYSEFri, Oct 24, 2014 4:04 PM EDT